Avar
Drug Antibacterial (topical)
NDC 0178-0480-08
General payments
$23,074
Research payments
$0
Through program year 2023, $23,074 in general payments and $0 in research payments were reported against Avar (Antibacterial (topical)).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $74 | 5 |
| 2022 | General | $3,654 | 223 |
| 2021 | General | $6,228 | 429 |
| 2020 | General | $3,519 | 220 |
| 2019 | General | $9,598 | 616 |
Breakdown
Each share is of general payments naming this product in 2023.
Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2023 where a state was reported.
Records
1,493 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.